Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for ... CVS Health also said Thursday that it will start selling Wegovy at a discounted price of about $500 monthly ...

Eli Lilly on Thursday downplayed CVS Health’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...

Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.

CVS plans to exit ACA individual exchanges, strikes Wegovy deal with Novo Nordisk Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with ...

CVS Health selected former Eli Lilly CFO Derica Rice to serve as the president of its pharmacy benefit management division, CVS Caremark, according to The Wall Street Journal. Effective March 30 ...

Patients taking Zepbound will be able to switch to Wegovy if the Lilly drug is excluded from their coverage, Whitrap said. CVS Health also said Thursday that it will start selling Wegovy at a ...